Keith Greenfield

Keith Greenfield is an accomplished professional in the biotechnology and financial sectors, currently serving as Director at AZTherapies, Inc., Phage Nova Bio, Inc., Hoo.be by FNL Technologies, and Xylyx Bio, Inc., while also holding the position of Founder and Director at Natur Unique International and Hessian Labs. With a strong background in business development, Keith acts as a Business Development Advisor to the CEO at GENERAL FLUIDICS CORPORATION and has a rich history as the Founder and President of The Dover Group, a financial planning firm. Previous experience includes Co-Founder and Executive Vice President of Corporate Development at IQuum, where a significant acquisition took place, and leading NanoTomer through notable accelerator programs. Keith holds a Bachelor of Applied Science in Finance from the Questrom School of Business at Boston University.